Table 4.
Associations between metformin use and cognitive function.
| β | 95% CI | p | |
|---|---|---|---|
| CERAD-IR | |||
| Model 1 | 0.776 | −0.321 to 1.874 | 0.159 |
| Model 2 | 0.126 | −0.847 to 1.100 | 0.793 |
| Model 3 | 0.027 | −1.060 to 1.113 | 0.960 |
| CERAD-DR | |||
| Model 1 | 0.568 | −0.122 to 1.257 | 0.103 |
| Model 2 | 0.347 | −0.299 to 0.993 | 0.282 |
| Model 3 | 0.353 | −0.324 to 1.031 | 0.295 |
| DSST | |||
| Model 1 | 7.406 | 4.373 to 10.440 | <0.001 |
| Model 2 | 4.745 | 1.942 to 7.547 | 0.002 |
| Model 3 | 4.184 | 1.655 to 6.713 | 0.002 |
| AF | |||
| Model 1 | 1.362 | 0.270 to 2.454 | 0.016 |
| Model 2 | 0.341 | −0.613 to 1.296 | 0.471 |
| Model 3 | 0.194 | −0.904 to 1.293 | 0.721 |
Participants with administration of oral hypoglycemic agents and insulin (n = 511) were included in the analysis.
Model 1 was univariate; Model 2 was adjusted for age, gender, race, education, sleep disorder, history of stroke, history of hyperlipidemia, BMI and SBP. Model 3 was Model 2 + smoking and alcohol consumption.
SE, standard error; CI, confidence interval; CERAD-IR, Consortium to Establish a Registry for Alzheimer’s Disease Immediate Recall; CERAD-DR, Consortium to Establish a Registry for Alzheimer’s Disease Delayed Recall; DSST, Digit Symbol Substitution Test; AF, Animal Fluency Test.